Go to Top
X

Services

Cancer Detect Profiles (Hereditary)
AEON’s cancer genomics testing analyzes mutations in a patient’s DNA known to be associated with an increased risk of hereditary cancer. AEON provides a comprehensive report indicating a patient’s potential susceptibility to various hereditary cancers. This testing uses the latest next generation sequencing technology to analyze patient samples in a rapid and accurate fashion.

This information helps guide a clinician’s route of personalized therapy dependent on the specific genomic mutation and associated cancer. Currently, AEON offers the analysis of thirtyseven (37) genes covering eighteen (18) different cancers as shown below:

**Click on the Gene to learn more about it**

Gene(s) Associated Cancer(s)/Tumor(s)
APC Colorectal, central nervous system, thyroid, liver, duodenal, pancreatic
ATM Breast, pancreatic
NBN Breast, prostate, possibly ovarian
BRCA1, BRCA2 Breast, ovarian, prostate, pancreatic, male breast
BRIP1, RAD51C,
RAD51D
Breast, ovarian
BMPR1A, SMAD4 Stomach, colorectal, pancreatic
CDH1 Breast, colorectal, gastric
CDK4 Melanoma
CDKN2A Melanoma, pancreatic
CHEK2 Breast, colorectal
FH Kidney, leiomyomas
FLCN Kidney
MAX Pheochromocytoma
MLH1, MSH2,
MSH6, PMS2,
EPCAM
Ovarian, colorectal, uterine, stomach, small bowel, hepatobiliary, brain,
pancreatic, sebaceous, urinary tract
MUTYH Breast, colorectal
NF1 Optic glioma, gastrointestinal stromal tumor,
paraganglioma/pheochromocytoma, neurofibromas, breast, Central
nervous system
PALB2 Breast, pancreatic
PTEN Breast, uterine, thyroid, colorectal, kidney
RET Thyroid (medullary), Pheochromocytoma
SDHAF2, SDHB,
SDHC, SDHD
Kidney, paraganglioma/pheochromocytoma, gastrointestinal stromal
tumor
TSC1, TSC2 Kidney, cardiac rhabdomyomas, central nervous system
STK11 Colorectal, small bowel, pancreatic, breast, ovarian
TMEM127 Paraganglioma/pheochromocytoma
TP53 Brain, leukemia, breast, sarcoma, adrenocortical, gastrointestinal,
genitourinary
VHL Kidney, pheochromocytoma, central nervous system

You could be at an increased risk for hereditary cancer if you or your family has a history of any of the following:

  • An individual having more than one (1) cancer
  • An individual who has multiple close family members under the age of fifty (50) with a cancer diagnosis
  • An individual having three (3) or more close family members with different types of cancer
  • An individual having a family that has previously had cancer genetic testing and mutations were identified

Benefits for the Ordering Physician

If standard treatments have failed, such as chemotherapy, cancer patients often need more targeted, personalized treatment plans. The genomic tests available at Aeon uncover patientspecific variants that predict response to treatment. Some of the specific benefits and advantages of the tests include:

  • Genomic profiling to enable more personalized patient care and treatment efficient, cost-effective and sensitive somatic variant analysis
  • Advantages of our Next Generation Sequencing (NGS) assays
    • Additional predictive targets for improved and more immediate clinical utility of tests
    • Wide range of variant types detected, including substitutions, insertions, deletions, and multiple structural rearrangements
    • Comprehensive reports with easy-to-understand result summaries and interpretations

AEON cancer genomics reports are easy to read and provide you with clinically significant data based on the most recent medical literature. Trust AEON’s cancer genomics testing services for your patients.